Form 4: Zivo Bioscience CEO Buys Shares in Open Market

Zivo Bioscience's President and CEO, John Bernard Payne, acquired 11,709 shares of common stock at $8.54 per share, increasing his direct beneficial ownership.

Summary

• John Bernard Payne, President and CEO, and a Director of Zivo Bioscience, Inc. (ZIVO), acquired 11,709 shares of common stock.
• The transaction occurred on January 26, 2026, at a price of $8.54 per share.
• Following this acquisition, Mr. Payne directly beneficially owns 19,618 shares of Zivo Bioscience common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.
• The Form 4 filing was submitted on January 28, 2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the insider purchase by the CEO, which typically signals confidence. However, the unusual future transaction date in the filing introduces a minor element of uncertainty or potential error, slightly tempering the overall positive sentiment.

Positives

• Insider buying by the President and CEO, John Bernard Payne, signals confidence in the company's future prospects.
• The acquisition was executed at a price of $8.54 per share, indicating management's belief in the stock's value at that level.
• The transaction was conducted under a Rule 10b5-1 plan, suggesting a pre-planned and systematic approach to share acquisition.

Negatives

• The reported transaction date of January 26, 2026, is in the future relative to the filing date of January 28, 2026, which is highly unusual for a Form 4 and suggests a potential clerical error in the filing.

Risks

• Potential for misreporting or clerical error in the SEC filing regarding the transaction date, which could lead to confusion or misinterpretation of the event.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic direction; it solely reports an insider transaction.

Industry Context

Insider purchases, especially by a CEO, are generally viewed by the market as a positive signal, indicating management's belief in the company's intrinsic value and future growth potential, often outperforming broader market trends or competitors facing similar challenges.

Corporate Governance

Related Party Transactions

• Acquisition of 11,709 shares of common stock by John Bernard Payne, President and CEO, and a Director of Zivo Bioscience, Inc., at $8.54 per share.

Stakeholder Impact

• Shareholders may perceive the CEO's purchase as a positive indicator of management's confidence in the company's future, potentially influencing investor sentiment and stock valuation.
• Employees may view the CEO's investment as a sign of stability and belief in the company's long-term success.

Key Dates

Keywords

Zivo Bioscience, ZIVO, Insider Trading, Form 4, Stock Purchase, CEO, John Bernard Payne, Equity Acquisition, 10b5-1 Plan